In recent years, prostate-specific membrane antigen (PSMA) targeted radioligand therapy with [177Lu]Lutetium PSMA-617 (LuPSMA) has emerged as a promising treatment option for patients with advanced prostate cancer 1. The gene discussed is FOLH1; the disease is prostate carcinoma.